Learn More
As has been shown by a number of working groups, primary fibromyalgia syndrome does not represent a single clinical entity. It is possible to distinguish between a subgroup with high pain sensitivity and no associated psychiatric condition, a second and a third subgroup characterized by depression associated with fibromyalgia syndrome, and a fourth group(More)
Fibromyalgie-Patienten mit einem Beck’schen Depressionsinventar <19 (Gruppe 1) ohne vorhergehende antidepressive Behandlung zeigten unter einer Therapie mit dem 5-HT3-Rezeptor-Antagonisten Tropisetron eine stärkere Schmerzlinderung im Vergleich zu Patienten mit einem Beck’schen Depressionsinventar ≥19 (Gruppe 2 und 3). Unter letzteren wiesen Patienten, die(More)
Microheterogeneity of two acute phase glycoproteins, α-1-acid glycoprotein (AGP) and α-1-antichymotryspin (ACT), concentrations of AGP, ACT, and C-reactive protein (CRP), and levels of three cytokines: interleukin 1 β (IL-1-β), interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α) were determined in 61 serum samples and 7 synovial fluids (SFs) obtained(More)
In fibromyalgia as well as in low back pain we frequently find disturbances of the posture of vertebral column clinically and radiologically. Also, reduction in the mobility of whole spine and localized movement impairments in both conditions was present. It is likely that the disturbances are responsible for the first manifestations of fibromyalgia in a(More)
Die lokale Injektion des 5-HT3-Rezeptor- Antagonisten Tropisetron zeigt bei den verschiedenen lokalen Erkrankungen im Bereich des Bewegungsapparats wie Tendinopathien, Periarthropathien,myofaszialen Schmerzzuständen, bei Trigger points und entzündlichen Gelenkprozessen einen deutlichen analgetischen Effekt.Dieser entspricht demjenigen der gebräuchlichen(More)
  • 1